Clear All
12482 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
60505-4533-02 60505-4533 Lenalidomide Lenalidomide 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sep 6, 2022 In Use
00603-5339-31 00603-5339 Prednisone Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Feb 12, 2003 Jul 14, 2017 In Use
39822-2080-01 39822-2080 Eribulin mesylate ERIBULIN MESYLATE 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous Apr 7, 2026 In Use
71335-2974-09 71335-2974 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Apr 6, 2026 In Use
71335-9715-04 71335-9715 PREDNISONE Prednisone 50.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Apr 9, 2026 In Use
71335-2500-05 71335-2500 Dexamethasone Dexamethasone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sep 23, 2024 In Use
72789-0475-40 72789-0475 PredniSONE PredniSONE Tablets, USP, 10 mg 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sep 3, 2025 In Use
50242-0245-86 50242-0245 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous May 3, 2021 In Use
76420-0376-30 76420-0376 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jun 19, 2025 In Use
50242-0245-01 50242-0245 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous Jun 29, 2020 In Use
00004-0365-09 00004-0365 Peginterferon alfa-2a Pegasys 180.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous Nov 1, 2011 In Use
63187-0065-10 63187-0065 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Apr 1, 2014 In Use
72205-0154-04 72205-0154 NELARABINE NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Oct 22, 2024 In Use
72205-0238-64 72205-0238 Nilotinib Nilotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Nov 20, 2025 In Use
64842-1020-03 64842-1020 Trifluridine and Tipiracil Lonsurf 8.19 mg/1, 20.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Oct 21, 2015 In Use
68001-0708-25 68001-0708 Palonosetron Hydrochloride Palonosetron 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Jul 15, 2026 In Use
00409-4755-02 00409-4755 Ondansetron Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Aug 29, 2007 Aug 1, 2010 In Use
00006-0072-31 00006-0072 Finasteride Proscar 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Jun 19, 1992 In Use
00069-0197-30 00069-0197 Dacomitinib Vizimpro 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 4, 2018 Dec 31, 2029 In Use
00069-1198-30 00069-1198 Dacomitinib Vizimpro 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 4, 2018 Sep 30, 2028 In Use
16714-0676-01 16714-0676 Sunitinib malate Sunitinib malate 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Feb 18, 2022 Sep 30, 2026 In Use
00006-0072-58 00006-0072 Finasteride Proscar 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Jun 19, 1992 In Use
00006-0464-01 00006-0464 Aprepitant Emend 40.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Mar 26, 2003 In Use
00006-0464-05 00006-0464 Aprepitant Emend 40.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Oral Mar 26, 2003 Dec 31, 2020 In Use
63304-0096-30 63304-0096 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov 5, 2019 In Use

Found 12482 results — Export these results